Endocrinopathy Clinical Trial
Official title:
Immune Checkpoint Inhibitor Therapy- Induced Endocrinopathy and Metabolic Diseases -a Case Series of Taiwanese Patients
To review cases from NTUH who developed endocrinopathy and metabolic diseases after immunotherapy, and statistically analyzed their age, clinical presentation, image findings, treatment and its response.
Immune checkpoint blockade-based immunotherapy is a new modality of cancer treatment with a
unique mechanism that has gained increased numbers of indication and is now used in several
cancer types. However, immune-related adverse events (irAEs) emerge as a new entity of
diseases involving one or multiple organ systems. irAEs could result in interruption of
immunotherapy, morbidities of patients or even death. Among various manifestations of irAEs,
endocrinopathy and metabolic diseases are rare but important, and require prompt diagnosis
and treatment to avoid life-threatening conditions.
Thus, we intend to review cases from NTUH who developed endocrinopathy and metabolic diseases
after immunotherapy, and statistically analyzed their age, clinical presentation, image
findings, treatment and its response. We will also review literatures to evaluate the
difference and similarity from previous diagnostic and treatment experience.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06137079 -
"Iron Overload and Endocrinological Diseases"
|
||
| Not yet recruiting |
NCT04261101 -
Test-enhanced Learning to Prepare for Future Learning in Endocrinology
|
N/A |